GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opiant Pharmaceuticals Inc (STU:8OP) » Definitions » Median PS Value

Opiant Pharmaceuticals (STU:8OP) Median PS Value : €0.00 (As of May. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Opiant Pharmaceuticals Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Opiant Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 was €3.616. Opiant Pharmaceuticals's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is €0.00.

As of today (2024-05-25), Opiant Pharmaceuticals's share price is €21.20. Opiant Pharmaceuticals's Median PS Value is €0.00. Therefore, Opiant Pharmaceuticals's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Opiant Pharmaceuticals's Median PS Value or its related term are showing as below:

STU:8OP's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.68
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Opiant Pharmaceuticals Median PS Value Historical Data

The historical data trend for Opiant Pharmaceuticals's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opiant Pharmaceuticals Median PS Value Chart

Opiant Pharmaceuticals Annual Data
Trend Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Dec18 Dec19 Dec20 Dec21
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Opiant Pharmaceuticals Quarterly Data
Oct17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Opiant Pharmaceuticals's Median PS Value

For the Biotechnology subindustry, Opiant Pharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Opiant Pharmaceuticals's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opiant Pharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Opiant Pharmaceuticals's Price-to-Median-PS-Value falls into.



Opiant Pharmaceuticals Median PS Value Calculation

Opiant Pharmaceuticals's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=3.616*0
=0.00

10-Year Median PS Ratio is 0.
Opiant Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.616.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Opiant Pharmaceuticals  (STU:8OP) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Opiant Pharmaceuticals's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=21.20/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Opiant Pharmaceuticals Median PS Value Related Terms

Thank you for viewing the detailed overview of Opiant Pharmaceuticals's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Opiant Pharmaceuticals (STU:8OP) Business Description

Traded in Other Exchanges
N/A
Address
233 Wilshire Boulevard, Suite 280, Santa Monica, CA, USA, 90401
Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD) and Acute Cannabinoid Overdose (ACO). The majority of the revenue is generated in the form of Royalty and licensing.

Opiant Pharmaceuticals (STU:8OP) Headlines

No Headlines